In this presentation, Nathalie MAUBON (CEO HCS Pharma), give an overview of drugs discovery, from pre-19th century are, where trials are done on humans, to nowadays where clinical trials are safer but with a dramatic rate of failure. She explains what are the “target base screening” and the “phenotypic screening in 2D” in pharmaceutical industries, why they are irrelevant to find drugs against complex deceases, and very inefficient to build the healthcare with the next 50 years.

Nathalie shows the importance to consider not only cells in drugs discovery but also the whole organ (cells, extracellular matrix, communication with other organs) to prepare the next step of personalized and regenerative medicine.

This discussion is illustrated by concrete examples realized with BIOMIMESYS® by HCS Pharma and partners.

Questions or/and comments? Send a message to our CEO

Grégory MAUBON

Grégory MAUBON is Chief Data Officer and digital coordinator at HCS Pharma, a biotech startup focused in high content screening and complex diseases. He manages IT missions and leads digital usages linked to company needs. He is also a Augmented Reality Evangelist (presenter and lecturer) since 2008, where he created and founded in 2010 RA'pro (the augmented reality promotion association). He helped many companies (in several domains) to define precisely their augmented reality needs and supported them in the implementation.


Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.